Index et al. partially exit Funxional Therapeutics

Previous funding
Index and Novo invested in a 2006 series-A round for Funxional to initiate research and development activities.

The round was followed by a €10m series-B financing in 2010 led by French investment firm Ventech, joined by Index and Novo. The money helped the business develop its medication known as broad spectrum chemokine inhibitors (BSCIs) or chemotides.

Company
Funxional is a privately held, clinical stage pharmaceutical company that was set up in 2006 following findings by Dr David Grainger and his colleagues at Cambridge University.

The company concentrates on anti-inflammatory therapies. Its lead product is FX 125L, an orally administered medication that reduces swelling.

People
Michele Ollier is partner at Index and chairman of the company's board.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• Healthcare
• UK / Ireland
• United Kingdom
• Germany
• Partial sale
• Index Ventures